Efficacy and safety of fixed‑duration pirtobrutinib plus venetoclax–rituximab (PVR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Chinese subgroup results from a randomized, phase 3 study (BRUIN CLL-322)

Rituxan (rituximab) - Roche

Venclexta (venetoclax) - Roche, AbbVie

Jaypirca (pirtobrutinib) - Eli Lilly

Efficacy and safety of fixed‑duration pirtobrutinib plus venetoclax–rituximab (PVR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Chinese subgroup results from a randomized, phase 3 study (BRUIN CLL-322) (ESMO Asia 2026) - Oct 1, 2026 - Abstract #1142eP; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • P3 data • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Small Lymphocytic Lymphoma

https://cslide.ctimeetingtech.com/asia2026/attendee/confcal/print/presentation/279

Hongling Peng; Huayuan Zhu; Jie Jin; Xiaoli Yuan; Guohui Cui; Yujun Dong; Da Gao; Qingsong Yin; Xiaoxi Zhou; Wei Yang; Ligen Liu; Xiuhui Ye; Jiankun Zhu; Toby A. Eyre; Jianyong Li

Oct 1, 2026